Continuous glucose monitoring gains traction in hospitals
An article in the February ACP Hospitalist covers how some hospitals have rapidly transitioned inpatient continuous glucose monitoring from research into practice in response to COVID-19.
Formerly confined to the outpatient setting except in the realm of research, continuous glucose monitoring (CGM) devices got the green light for in-hospital use in April 2020 when the FDA told manufacturers it would not object to such use during the pandemic. Researchers are still determining whether the devices are as reliable as in the outpatient setting, but more than 100 hospitals in the U.S. are currently using them, experts said. In the latest issue of ACP Hospitalist, they describe current use of CGM in hospitals and the potential benefits and challenges of wider inpatient implementation.